These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

501 related items for PubMed ID: 23808937

  • 1. Effects of switching acute treatment on disability in migraine patients using triptans.
    Serrano D, Buse DC, Kori SH, Papapetropoulos S, Cunanan CM, Manack AN, Reed ML, Lipton RB.
    Headache; 2013 Oct; 53(9):1415-29. PubMed ID: 23808937
    [Abstract] [Full Text] [Related]

  • 2. Adding Additional Acute Medications to a Triptan Regimen for Migraine and Observed Changes in Headache-Related Disability: Results From the American Migraine Prevalence and Prevention (AMPP) Study.
    Buse DC, Serrano D, Reed ML, Kori SH, Cunanan CM, Adams AM, Lipton RB.
    Headache; 2015 Jun; 55(6):825-39. PubMed ID: 25881857
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Rates and predictors of starting a triptan: results from the American Migraine Prevalence and Prevention Study.
    Bigal ME, Buse DC, Chen YT, Golden W, Serrano D, Chu MK, Lipton RB.
    Headache; 2010 Oct; 50(9):1440-8. PubMed ID: 20533956
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Migraine-related healthcare resource use and costs for subjects prescribed fixed-dose combination sumatriptan/naproxen sodium vs. single-entity oral triptans in a managed care population in the USA.
    Runken MC, Goodwin B, Shah M, Eaddy M, D'Souza A, Bowers B, Bell CF.
    Appl Health Econ Health Policy; 2015 Feb; 13(1):109-20. PubMed ID: 25294555
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Acute treatment optimization in episodic and chronic migraine: results of the American Migraine Prevalence and Prevention (AMPP) Study.
    Serrano D, Buse DC, Manack Adams A, Reed ML, Lipton RB.
    Headache; 2015 Apr; 55(4):502-18. PubMed ID: 25881676
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Acute Migraine Treatment in Adults.
    Becker WJ.
    Headache; 2015 Jun; 55(6):778-93. PubMed ID: 25877672
    [Abstract] [Full Text] [Related]

  • 16. Chronic migraine prevalence, disability, and sociodemographic factors: results from the American Migraine Prevalence and Prevention Study.
    Buse DC, Manack AN, Fanning KM, Serrano D, Reed ML, Turkel CC, Lipton RB.
    Headache; 2012 Jun; 52(10):1456-70. PubMed ID: 22830411
    [Abstract] [Full Text] [Related]

  • 17. Identifying the factors underlying discontinuation of triptans.
    Wells RE, Markowitz SY, Baron EP, Hentz JG, Kalidas K, Mathew PG, Halker R, Dodick DW, Schwedt TJ.
    Headache; 2014 Feb; 54(2):278-89. PubMed ID: 24001117
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Health care resource utilization following initiation of a triptan: a retrospective claims analysis.
    Messali A, Owens G, Bloudek L, Kori S, Cole A, Chia J.
    J Manag Care Spec Pharm; 2014 Apr; 20(4):368-75. PubMed ID: 24684641
    [Abstract] [Full Text] [Related]

  • 20. A cross-sectional survey to assess the migraineur's medication decision-making beliefs: determining when a migraine is triptan-worthy.
    Landy SH, Turner IM, Runken MC, Lee M, Sulcs E, Bell CF.
    Headache; 2013 Apr; 53(7):1134-46. PubMed ID: 23773016
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.